检索结果-南通市图书馆

A randomized clinical trial investigating treatment choice in Chinese men receiving sildenafil citrate and tadalafil for treating erectile dysfunction

引用

Asian Journal of Andrology 2017年第4期19卷 500-504页

作者： Wen-Jun Bai Hong-Jun Li Jian-Jun Jin Wen-Ping Xu sorsaburu sebastian Xiao-Feng Wang Department of Urology Peking University People's Hospital Beijing 100044 China Department of Urology Peking Union Medical College Hospital Beijing 100730 China Department of Medical Lilly Suzhou Pharmaceutical Co. Ltd. Shanghai 200021 China Eli Lilly and Company Indianapolis Indiana 46285 USA

Sildenafil and tadalafil are efficacious and well tolerated in Chinese men with erectile dysfunction （ED）. Recent study results indicate that men with ED in China who were naive to phosphodiesterase inhibitor type 5 （PDE5） therapy prefer tadalafil 20-mg （on-demand） versus sildenafil 100-mg （on-demand）. Differences in psychosocial outcomes may help to explain treatment preference in favor of tadalafih This open-label, randomized, crossover study compared psychosocial outcomes and drug attribute choices between tadalafil and sildenafil in Chinese men with ED na＇（ve to PDE5 inhibitor therapy. Eligible patients were randomized to sequential 20-mg tadalafU/lOO-mg sildenafil （n = 190） or 100-mg sildenafil/20-mg tadalafil （n = 193） for 8 weeks each and were asked which treatment they preferred to take for the 8-week extension phase. Psychosocial outcomes were assessed using the Psychological and Interpersonal Relationship Scale （PAIRS）, Drug Attributes Questionnaire （DRAQ）, and Sexual Life Quality Questionnaire （SLQQ）. When taking tadalafil versus sildenafil, men had a higher mean endpoint score on the PAIRS Spontaneity Domain （tadalafil = 2.86 vs sildenafil = 2.72; P 〈 0.001）, and a lower mean endpoint score on the Time Concerns Domain （tadalafil = 2.41 vs sildenafil = 2.55; P 〈 0.001）. A numerical increase in the Sexual Self-Confidence Domain was observed when taking tadalafil versus sildenafil （tadalafil -- 2.76 vs sildenafil = 2.72; P= 0.102）. The most frequently chosen drug attributes explaining treatment preference were able to get an erection long after having drug, and ability to get an erection every time. SLQQ results were comparable between treatment groups. These psychosocial outcomes may explain why more Chinese men preferred tadalafil versus sildenafil for the treatment of ED in this clinical trial.

关键词： drug attributes erectile dysfunction phosphodiesterase type 5 inhibitor psychological assessment of sexual dysfunction

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalahl for treating erectile dysfunction in Chinese men na＇=＇ve to phosphodiesterase 5 .inhibitor therapy

引用

Asian Journal of Andrology 2015年第1期17卷 61-67,I0007,I0008页

作者： Wen-Jun Bai Hong-Jun Li Yu-Tian Dai Xue-You He Yi-Ran Huang Ji-Hong Liu sebastian sorsaburu Chen Ji Jian-Jun Jin Xiao-Feng Wang Department of Urology People's Hospital of Peking University Beijing China Department of Urology Peking Union Medical College Hospital Beijing China Department of Andrology Nanjing Drum Tower Hospital Jiangsu China Department of Urology Chinese PLA General Hospital Beijing China Department of Urology Shanghai Renji Hospital Shanghai China Department of Urology Tongji Hospital Tengji Medical College of Huazhong University of Science and Technology Wuhan China Department of Medical Eli Lilly and Company Indianapolis IN USA Department of Medical Lilly Suzhou Pharmaceutical Co. Ltd. Shanghai China.

The study was to compare treatment preference, efficacy, and tolerability of sildenafil citrate （sildenafil） and tadalafil for treating erectile dysfunction （ED） in Chinese men na＇ive to phosphodiesterase 5 （PDE5） inhibitor therapies. This multicenter, randomized, open-label, crossover study evaluated whether Chinese men with ED preferred 20-mg tadalafil or 100-mg sildenafil. After a 4 weeks baseline assessment, 383 eligible patients were randomized to sequential 20-mg tadalafil per 100-mg sildenafil or vice versa for 8 weeks respectively and then chose which treatment they preferred to take during the 8 weeks extension. Primary efficacy was measured by Question 1 of the PDE5 Inhibitor Treatment Preference Questionnaire （PITPQ）. Secondary efficacy was analyzed by PITPQ Question 2, the International Index of Erectile Function （IIEF） erectile function （EF） domain, sexual encounter profile （SEP） Questions 2 and 3, and the Drug Attributes Questionnaire. Three hundred and fifty men （91%） completed the randomized treatment phase. Two hundred and forty-two per 350 （69.1%） patients preferred 20-mg tadalafil, and 108/350 （30.9%） preferred lO0-mg sildenafil （P 〈 0.001） as their treatment in the 8 weeks extension. Ninety-two per 242 （38%） patients strongly preferred tadalafil and 37/108 （34.3%） strongly the preferred sildenafil. The SEP2 （penetration）, SEP3 （successful intercourse）, and IIEF-EF domain scores were improved in both tadalafil and sildenafil treatment groups. For patients who preferred tadalafil, getting an erection long after taking the medication was the most reported reason for tadalafil preference. The only treatment-emergent adverse event reported by 〉 2% of men was headache. After tadalafil and sildenafil treatments, more Chinese men with ED na＇ive to PDE5 inhibitor preferred tadalafil. Both sildenafil and tadalafil treatments were effective and safe.

关键词： erectile dysfunction patient preference phosphodiesterase 5 inhibitors

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

特立帕肽（重组人甲状旁腺素1—34）在骨质疏松治疗中的应用

引用

中华内分泌代谢杂志 2013年第12期29卷 I0004-I0010页

作者：骆天红礼来苏州制药有限公司上海分公司 200021

特立帕肽是一种注射用人重组甲状旁腺素，已在全球范围内被批准用于治疗骨质疏松症，在2011年进入中国。临床前研究显示，通过不同于包括双膦酸盐、选择性雌激素受体调节剂（selectiveestrogenreceptormodulators，SERMs）、降钙素和雌... 详细信息

特立帕肽是一种注射用人重组甲状旁腺素，已在全球范围内被批准用于治疗骨质疏松症，在2011年进入中国。临床前研究显示，通过不同于包括双膦酸盐、选择性雌激素受体调节剂（selectiveestrogenreceptormodulators，SERMs）、降钙素和雌激素在内的其他抗骨吸收药物的独特作用机制，特立帕肽可起到促进骨形成的作用。在男性和绝经后妇女中进行的临床试验已证实特立帕肽有成骨作用，并可降低骨折风险，升高骨转换标志物（包括血清骨钙素和I型前胶原N末端肽[***，PINP]、骨密度[bonemineraldensity，BMD]）及改善骨质量。最近，在亚裔人群中进行的临床试验也已得出相似结论，并证实与目前的抗骨吸收药物相比，特立帕肽可提高骨标志物和骨密度。

关键词：骨标志物骨密度骨质量骨折骨质疏松特立帕肽

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：